top of page

MYX

Mayne Pharma Group Ltd

Pharmaceuticals

·

Healthcare

2

comments

1

fund manager

past 90 days

About Mayne Pharma Group Ltd

Headquartered in Salisbury, Australia, and founded in 1845, Mayne Pharma Group Ltd. develops and manufactures proprietary and generic pharmaceutical products. The company operates through four segments: Generic Products, manufacturing and distributing generic and branded pharmaceuticals; Specialty Products, focusing on branded distribution; Metrics Contract Services, providing pharmaceutical contract services; and Mayne Pharma International, which manages sales, distribution, and third-party contract manufacturing in Australia. Mayne Pharma integrates these divisions to offer comprehensive pharmaceutical development and commercialization.

Commentary Volume

2

Comments

1

Fund managers

0

Past 90 days

SOURCE

ACTION

COMMENT PREVIEW

FUND MANAGER

DATE

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Loading...

.

​Loading...

Loading...

Loading...

Loading...

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Report a problem

Loading...

.

Loading...

Loading...

Loading...

Loading...

14 Mar 2025

ic

Ipsum Capital

"Lorem ipsum dolor sit amet...

Q4 Letter

14 Mar 2025

ic

Dolor Investments

"Lorem ipsum dolor sit amet...

Q4 Letter

🔒 21 more comments from 10 sources

Unlock full access

§ Important Notice

The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Commentary

Sector

Healthcare

Market cap

$186M

Fund managers

1 manager

First covered

22 May 2025

Last updated

10 July 2025

Company Details

Related Themes

ic

Ipsum Capital

6 comments

ic

Amet Funds

4 comments

ic

Dolor

3 comments

Top Investors Covering MIN

§ Reminder

The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Frequently asked questions about Mayne Pharma Group Ltd (ASX:MYX)

Frequently asked questions

Who is investing in Mayne Pharma Group Ltd (ASX:MYX)?

Fund managers including Harvest Lane Asset Management have invested in Mayne Pharma Group Ltd (ASX:MYX).

What is the short interest in Mayne Pharma Group Ltd (ASX:MYX)?

The short interest in Mayne Pharma Group Ltd (ASX:MYX) is 1.81% which makes it the 146th most shorted stock on the ASX. Of the 81.2M shares that Mayne Pharma Group Ltd has on issue, 1.5M have been sold short.

What does Mayne Pharma Group Ltd (ASX:MYX) do?

Headquartered in Salisbury, Australia, and founded in 1845, Mayne Pharma Group Ltd. develops and manufactures proprietary and generic pharmaceutical products. The company operates through four segments: Generic Products, manufacturing and distributing generic and branded pharmaceuticals; Specialty Products, focusing on branded distribution; Metrics Contract Services, providing pharmaceutical contract services; and Mayne Pharma International, which manages sales, distribution, and third-party contract manufacturing in Australia. Mayne Pharma integrates these divisions to offer comprehensive pharmaceutical development and commercialization.

bottom of page